You are here

  • Home
  • Archive
  • Volume 51, Issue 5
  • Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma

Article Text

Article menu
Download PDFPDF
Pancreas
Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma
  1. F Maire1,
  2. P Hammel1,
  3. B Terris2,
  4. F Paye1,
  5. J-Y Scoazec3,
  6. C Cellier4,
  7. M Barthet5,
  8. D O’Toole1,
  9. P Rufat6,
  10. C Partensky7,
  11. E Cuillerier4,
  12. P Lévy1,
  13. J Belghiti1,
  14. P Ruszniewski1
  1. 1Fédération Médico-Chirugicale d’Hépato-Gastroentérologie, Hôpital Beaujon, Clichy, France
  2. 2Service d’Anatomie Pathologique, Hôpital Beaujon
  3. 3Service d’Anatomie Pathologique, Hôpital Edouard Herriot, Lyon, Frrance
  4. 4Service d’Hépato-Gastroentérologie, Hôpital Laënnec, Paris, France
  5. 5Service d’Hépato-Gastroentérologie Hôpital Nord, Marseille, France
  6. 6Cellule MSI, Hôpital Beaujon
  7. 7Service de Chirurgie Viscérale, Hôpital Edouard Herriot
  1. Correspondence to:
    Dr F Maire, Fédération médico-chirurgicale d’Hépato-Gastroentérologie, Hôpital Beaujon 100, Boulevard du Général Leclerc, 92118 Clichy Cedex, France;
    frederique.maire{at}bjn.ap-hop-paris.fr

Abstract

Background: Although the prognosis in malignant resectable intraductal papillary mucinous tumours of the pancreas (IPMT) is often considered more favourable than for ordinary pancreatic ductal adenocarcinoma, the long term outcome remains ill defined.

Aims: To assess prognostic factors in patients with malignant IPMT after surgical resection, and to compare long term survival rates with those of patients surgically treated for ductal adenocarcinoma.

Methods: Seventy three patients underwent surgery for malignant IPMT in four French centres. Clinical, biochemical, and pathological features and follow up after resection were recorded. Patients with invasive malignant IPMT were matched with patients with pancreatic ductal adenocarcinoma, according to age and TNM stages; survival rates after resection were compared.

Results: Surgical treatment for IPMT were pancreaticoduodenectomy (n=46), distal (n=14), total (n=11), or segmentary (n=2) pancreatectomy. The operative mortality rate was 4%. IPMT corresponded to in situ (n=22) or invasive carcinoma (n=51). In the latter group, 17 had lymph node metastases. Overall median survival was 47 months. Five year survival rates in patients with in situ and invasive carcinoma were 88% and 36%, respectively. On univariate analysis, abdominal pain, preoperative high serum carbohydrate antigen 19.9 concentrations, caudal localisation, invasive carcinoma, lymph node metastases, peripancreatic extension, and malignant relapse were associated with a fatal outcome. Using multivariate analysis, lymph node metastases were the only prognostic factor (OR 7.5; 95% CI: 3.4 to 16.4). Overall five year survival rate was higher in patients with malignant invasive IPMT compared with those with pancreatic ductal carcinoma (36 v 21%, p=0.03), but was similar in the subset of stage II/III tumours.

Conclusions: The prognosis of patients with resected in situ/invasive stage I malignant IPMT is excellent. In contrast, prognosis of locally advanced forms is as poor as in patients with pancreatic ductal adenocarcinoma.

  • pancreas
  • intraductal papillary mucinous tumours
  • CA 19
  • 9, carbohydrate antigen 19
  • 9; CEA, carcinoembryonic antigen; IPMT, intraductal papillary mucinous tumours of the pancreas

https://doi.org/10.1136/gut.51.5.717

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes